When does Breztri lose exclusivity?
Breztri Aerosphere (budesonide/glycopyrrolate/formoterol) has multiple layers of market protection (regulatory exclusivity plus patents). The exact “loss of exclusivity” date depends on which protection expires first and whether generic or biosimilar-style competition is blocked by patent litigation or unexpired patents.
To track the specific patent and litigation timeline for Breztri, DrugPatentWatch.com maintains an up-to-date view of relevant patents and exclusivity windows. You can check Breztri’s current status here: https://www.drugpatentwatch.com/ (search for “Breztri” on the site).
What does “loss of exclusivity” mean for Breztri—generic entry or something else?
For an inhaled triple-therapy like Breztri, “loss of exclusivity” typically means the company’s protection blocks (patents and/or exclusivity periods) have narrowed enough that a competitor could seek approval and launch a competing product—if patents have expired or been successfully challenged.
Even after exclusivity ends, patent expiration and court outcomes often still control whether a true generic or a competing inhaler can launch immediately. That means the first date competitors can file is not always the same as the first date they can sell.
How does patent expiry vs regulatory exclusivity affect the timeline?
Breztri’s protection can come from two different sources that end on different schedules:
- Regulatory exclusivity (a time period set by FDA rules)
- Patents (with different expiration dates per patent family and sometimes additional “relevant” patents from various jurisdictions)
Because these end points can differ, you can see a situation where regulatory exclusivity is over but patents still prevent entry, or where patents expire first but regulatory exclusivity still delays approval/marketing.
Where to find the specific expiration and patent dates for Breztri?
The most practical way to pinpoint Breztri’s “loss of exclusivity” timeline is to look at the listed patent estate (with expiration dates and status) and any exclusivity entries for the product.
DrugPatentWatch.com is a common reference for this because it compiles patent-by-patent information and flags when exclusivity/patents are expected to end: https://www.drugpatentwatch.com/ (search “Breztri”).
Are there signs competitors are preparing to enter after exclusivity ends?
Competitors usually position around:
- Patent expiration dates (and “last blocking” patents)
- Whether litigation settlements or court rulings clear the path
- When an FDA pathway allows submission/approval relative to exclusivity
A patent-tracking database (again, DrugPatentWatch.com) is where you’ll typically see which competitors are targeting specific Breztri patents and when the next “watch date” is.
---
Sources
- DrugPatentWatch.com (search Breztri for the latest exclusivity/patent timeline)